P1117: GLOFITAMAB PLUS R-CHOP OR POLATUZUMAB VEDOTIN-R-CHP IS DELIVERABLE AND YIELDS HIGH OVERALL RESPONSE IN PATIENTS <=65 YEARS OF AGE WITH HIGH-RISK DLBCL OR HGBL: INTERIM ANALYSIS OF THE COALITION STUDY

• Adrian Minson,
• Emma Verner,
• Pratyush Giri,
• Shu Min Wong,
• Sumita Ratnasingam,
• Jason Butler,
• Wojciech Janowski,
• Matthew Ku,
• Chan Cheah,
• Mark Hertzberg,
• Kirsten Herbert,
• Nada Hamad,
• Costas Yannakou,
• Paul Neeson,
• Javad Saghebi,
• Piers Blombery,
• Molly Robertson,
• Lei Shong Lau,
• Jing Xie,
• John Seymour,
• Michael Dickinson

Affiliations

Adrian Minson

1 Peter MacCallum Cancer Centre, Melbourne, Australia

Emma Verner

4 Concord Repatriation General Hospital, Concord, Australia

Pratyush Giri

5 Royal Adelaide Hospital, Adelaide, Australia

Shu Min Wong

6 The Alfred Hospital, Melbourne, Australia

Sumita Ratnasingam

7 University Hospital Geelong, Geelong, Australia

Jason Butler

8 Royal Brisbane and Women’s Hospital, Herston, Australia

Wojciech Janowski

9 Calvary Mater Newcastle, Waratah, Australia

Matthew Ku

10 St. Vincent’s Hospital Melbourne, Fitzroy, Australia

Chan Cheah

11 Sir Charles Gairdner Hospital, Nedlands, Australia

Mark Hertzberg

12 Prince Of Wales Hospital, Randwick, Australia

Kirsten Herbert

1 Peter MacCallum Cancer Centre, Melbourne, Australia

Nada Hamad

14 St Vincent’s Hospital Sydney, Darlinghurst, Australia

Costas Yannakou

15 Epworth HealthCare, Melbourne, Australia

Paul Neeson

1 Peter MacCallum Cancer Centre, Melbourne, Australia

Javad Saghebi

1 Peter MacCallum Cancer Centre, Melbourne, Australia

Piers Blombery

1 Peter MacCallum Cancer Centre, Melbourne, Australia

Molly Robertson

1 Peter MacCallum Cancer Centre, Melbourne, Australia

Lei Shong Lau

1 Peter MacCallum Cancer Centre, Melbourne, Australia

Jing Xie

1 Peter MacCallum Cancer Centre, Melbourne, Australia

John Seymour

1 Peter MacCallum Cancer Centre, Melbourne, Australia

Michael Dickinson

1 Peter MacCallum Cancer Centre, Melbourne, Australia